# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Sarah James reiterates Elevance Health (NYSE:ELV) with a Overweight and maintains $600 price target.
Stephens & Co. analyst Scott Fidel reiterates Elevance Health (NYSE:ELV) with a Overweight and maintains $615 price target.
Evolent Health is exploring a potential sale, drawing interest from private equity firms like TPG and KKR.
- Reuters Citing Sources